MX394495B - Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo - Google Patents

Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo

Info

Publication number
MX394495B
MX394495B MX2020008488A MX2020008488A MX394495B MX 394495 B MX394495 B MX 394495B MX 2020008488 A MX2020008488 A MX 2020008488A MX 2020008488 A MX2020008488 A MX 2020008488A MX 394495 B MX394495 B MX 394495B
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
crystal form
oxopicolinamide
derivative
Prior art date
Application number
MX2020008488A
Other languages
English (en)
Other versions
MX2020008488A (es
Inventor
Junran Yang
Likun Wang
Lin Wang
Qiyun Shao
Zhenxing Du
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020008488A publication Critical patent/MX2020008488A/es
Publication of MX394495B publication Critical patent/MX394495B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan una forma cristalina de un derivado de oxopicolinamida y un método de preparación de la misma. En particular, se proporcionan formas cristalinas A, B, C, D, E y F de un compuesto como se muestra en la fórmula (I) y un método de preparación de las mismas. Las formas cristalinas A, B, C, D, E y F del compuesto de fórmula (I) obtenido en la presente descripción tienen buena estabilidad cristalina y estabilidad química, y se puede usar mejor en el tratamiento clínico.(VER FORMULA)
MX2020008488A 2018-02-27 2019-02-26 Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo MX394495B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810163529 2018-02-27
PCT/CN2019/076132 WO2019165951A1 (zh) 2018-02-27 2019-02-26 一种氧代吡啶酰胺类衍生物的晶型及其制备方法

Publications (2)

Publication Number Publication Date
MX2020008488A MX2020008488A (es) 2022-08-04
MX394495B true MX394495B (es) 2025-03-24

Family

ID=67804814

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008488A MX394495B (es) 2018-02-27 2019-02-26 Forma cristalina del derivado de oxopicolinamida y metodo de preparacion del mismo

Country Status (13)

Country Link
US (1) US11299462B2 (es)
EP (1) EP3741746A4 (es)
JP (1) JP2021514944A (es)
KR (1) KR20200127196A (es)
CN (1) CN111094241B (es)
AU (1) AU2019227332A1 (es)
BR (1) BR112020016856A2 (es)
CA (1) CA3091528A1 (es)
MX (1) MX394495B (es)
RU (1) RU2020125154A (es)
TW (1) TWI802654B (es)
UA (1) UA126251C2 (es)
WO (1) WO2019165951A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd FXA INHIBITORS AND METHODS OF PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF
WO2023208169A1 (zh) * 2022-04-29 2023-11-02 江苏恒瑞医药股份有限公司 一种凝血XIa抑制剂的离子液体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
WO2013093484A1 (en) 2011-12-21 2013-06-27 Ono Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
US9809545B2 (en) * 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015120777A1 (zh) * 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
JP6517925B2 (ja) * 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
WO2016046156A1 (de) * 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
AU2019227332A1 (en) 2020-08-27
UA126251C2 (uk) 2022-09-07
US20200385353A1 (en) 2020-12-10
KR20200127196A (ko) 2020-11-10
EP3741746A4 (en) 2020-12-16
WO2019165951A1 (zh) 2019-09-06
US11299462B2 (en) 2022-04-12
MX2020008488A (es) 2022-08-04
TW201936580A (zh) 2019-09-16
RU2020125154A (ru) 2022-03-28
CA3091528A1 (en) 2019-09-06
EP3741746A1 (en) 2020-11-25
TWI802654B (zh) 2023-05-21
JP2021514944A (ja) 2021-06-17
CN111094241B (zh) 2022-06-21
CN111094241A (zh) 2020-05-01
BR112020016856A2 (pt) 2020-12-22

Similar Documents

Publication Publication Date Title
EP4585268A3 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AU2016237099B2 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
AU2015352440B2 (en) Compounds
JOP20190254A1 (ar) مركبات مضادة للأورام
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
MX395263B (es) Forma cristalina de base libre de lorlatinib
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MX2024009894A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
EP4663247A3 (en) Formulations/compositions comprising a btk inhibitor
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
PH12022551241A1 (en) Egfr inhibitors
EP4364741A3 (en) Polymorphic form of tg02
WO2018125880A8 (en) Nrf2 activator
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MY198916A (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof